Literature DB >> 24221134

Anti-Candida activity of 1-18 fragment of the frog skin peptide esculentin-1b: in vitro and in vivo studies in a Caenorhabditis elegans infection model.

Vincenzo Luca1, Massimiliano Olivi, Antonio Di Grazia, Claudio Palleschi, Daniela Uccelletti, Maria Luisa Mangoni.   

Abstract

Candida albicans represents one of the most prevalent species causing life-threatening fungal infections. Current treatments to defeat Candida albicans have become quite difficult, due to their toxic side effects and the emergence of resistant strains. Antimicrobial peptides (AMPs) are fascinating molecules with a potential role as novel anti-infective agents. However, only a few studies have been performed on their efficacy towards the most virulent hyphal phenotype of this pathogen. The purpose of this work is to evaluate the anti-Candida activity of the N-terminal 1-18 fragment of the frog skin AMP esculentin-1b, Esc(1-18), under both in vitro and in vivo conditions using Caenorhabditis elegans as a simple host model for microbial infections. Our results demonstrate that Esc(1-18) caused a rapid reduction in the number of viable yeast cells and killing of the hyphal population. Esc(1-18) revealed a membrane perturbing effect which is likely the basis of its mode of action. To the best of our knowledge, this is the first report showing the ability of a frog skin AMP-derived peptide (1) to kill both growing stages of Candida; (2) to promote survival of Candida-infected living organisms and (3) to inhibit transition of these fungal cells from the roundish yeast shape to the more dangerous hyphal form at sub-inhibitory concentrations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24221134     DOI: 10.1007/s00018-013-1500-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  78 in total

Review 1.  The distinct morphogenic states of Candida albicans.

Authors:  Peter Sudbery; Neil Gow; Judith Berman
Journal:  Trends Microbiol       Date:  2004-07       Impact factor: 17.079

2.  Ultrashort antibacterial and antifungal lipopeptides.

Authors:  Arik Makovitzki; Dorit Avrahami; Yechiel Shai
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-12       Impact factor: 11.205

Review 3.  Growth of Candida albicans hyphae.

Authors:  Peter E Sudbery
Journal:  Nat Rev Microbiol       Date:  2011-08-16       Impact factor: 60.633

4.  Use of antifungal agents in pediatric and adult high-risk areas.

Authors:  E Ramírez; J García-Rodríguez; A M Borobia; J M Ortega; S Lei; A Barrios-Fernández; M Sánchez; A J Carcas; A Herrero; J M de la Puente; J Frías
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-01       Impact factor: 3.267

Review 5.  Multidrug resistance in yeast Candida.

Authors:  Rajendra Prasad; Khyati Kapoor
Journal:  Int Rev Cytol       Date:  2005

6.  In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

7.  Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection.

Authors:  Stephen P Saville; Anna L Lazzell; Carlos Monteagudo; Jose L Lopez-Ribot
Journal:  Eukaryot Cell       Date:  2003-10

8.  Antimicrobial peptides from skin secretions of Rana esculenta. Molecular cloning of cDNAs encoding esculentin and brevinins and isolation of new active peptides.

Authors:  M Simmaco; G Mignogna; D Barra; F Bossa
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

9.  Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).

Authors:  Olivier Leroy; Jean-Pierre Gangneux; Philippe Montravers; Jean-Paul Mira; François Gouin; Jean-Pierre Sollet; Jean Carlet; Jacques Reynes; Michel Rosenheim; Bernard Regnier; Olivier Lortholary
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

10.  Candida albicans infection of Caenorhabditis elegans induces antifungal immune defenses.

Authors:  Read Pukkila-Worley; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  PLoS Pathog       Date:  2011-06-23       Impact factor: 6.823

View more
  5 in total

1.  Derivatives of Esculentin-1 Peptides as Promising Candidates for Fighting Infections from Escherichia coli O157:H7.

Authors:  Raffaella Scotti; Bruno Casciaro; Annarita Stringaro; Fabrizio Morgia; Maria Luisa Mangoni; Roberta Gabbianelli
Journal:  Antibiotics (Basel)       Date:  2022-05-13

2.  Antifungal Activity of the Frog Skin Peptide Temporin G and Its Effect on Candida albicans Virulence Factors.

Authors:  Felicia Diodata D'Auria; Bruno Casciaro; Marta De Angelis; Maria Elena Marcocci; Anna Teresa Palamara; Lucia Nencioni; Maria Luisa Mangoni
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

3.  Effect of Dermaseptin S4 on C. albicans Growth and EAP1 and HWP1 Gene Expression.

Authors:  Johan Samot; Mahmoud Rouabhia
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

4.  Frog Skin-Derived Peptides Against Corynebacterium jeikeium: Correlation between Antibacterial and Cytotoxic Activities.

Authors:  Bruno Casciaro; Maria Rosa Loffredo; Floriana Cappiello; Walter Verrusio; Vito Domenico Corleto; Maria Luisa Mangoni
Journal:  Antibiotics (Basel)       Date:  2020-07-26

Review 5.  Antimicrobial Peptides: An Update on Classifications and Databases.

Authors:  Ahmer Bin Hafeez; Xukai Jiang; Phillip J Bergen; Yan Zhu
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.